Works matching IS 25785745 AND DT 2023 AND VI 5 AND IP 1


Results: 10
    1
    2
    3
    4
    5

    Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial.

    Published in:
    ACR Open Rheumatology, 2023, v. 5, n. 1, p. 38, doi. 10.1002/acr2.11511
    By:
    • Wallace, Daniel J.;
    • Dörner, Thomas;
    • Pisetsky, David S.;
    • Sanchez‐Guerrero, Jorge;
    • Patel, Anand C.;
    • Parsons‐Rich, Dana;
    • Le Bolay, Claire;
    • Drouin, Elise E.;
    • Kao, Amy H.;
    • Guehring, Hans;
    • Dall'Era, Maria
    Publication type:
    Article
    6
    7
    8
    9
    10

    Issue Information.

    Published in:
    ACR Open Rheumatology, 2023, v. 5, n. 1, p. 1, doi. 10.1002/acr2.11453
    Publication type:
    Article